Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Cash from Investing Activities (2021 - 2024)

Historic Cash from Investing Activities for Lyra Therapeutics (LYRA) over the last 4 years, with Q4 2024 value amounting to $28.1 million.

  • Lyra Therapeutics' Cash from Investing Activities rose 129249.68% to $28.1 million in Q4 2024 from the same period last year, while for Sep 2025 it was $72.4 million, marking a year-over-year increase of 4543.41%. This contributed to the annual value of $80.3 million for FY2024, which is 73815.16% up from last year.
  • Latest data reveals that Lyra Therapeutics reported Cash from Investing Activities of $28.1 million as of Q4 2024, which was up 129249.68% from $8.1 million recorded in Q3 2024.
  • Lyra Therapeutics' 5-year Cash from Investing Activities high stood at $36.2 million for Q2 2024, and its period low was -$64.9 million during Q4 2022.
  • For the 4-year period, Lyra Therapeutics' Cash from Investing Activities averaged around -$41875.0, with its median value being -$305000.0 (2021).
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first crashed by 5155172.41% in 2023, then soared by 654848.48% in 2024.
  • Lyra Therapeutics' Cash from Investing Activities (Quarter) stood at -$1.1 million in 2021, then crashed by 5889.84% to -$64.9 million in 2022, then skyrocketed by 96.36% to -$2.4 million in 2023, then skyrocketed by 1292.5% to $28.1 million in 2024.
  • Its last three reported values are $28.1 million in Q4 2024, $8.1 million for Q3 2024, and $36.2 million during Q2 2024.